(Q28079918)

English

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

scientific article

In more languages

Statements

scholarly article

1 reference

8 references

13 March 2019

3 April 2019

19 June 2019

25 June 2019

2 October 2019

2 August 2020

27 October 2020

16 July 2021

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (English)

1 reference

8 references

13 March 2019

3 April 2019

19 June 2019

25 June 2019

2 October 2019

2 August 2020

27 October 2020

16 July 2021

castration-resistant prostatic neoplasm

8 references

13 March 2019

3 April 2019

19 June 2019

25 June 2019

2 October 2019

2 August 2020

27 October 2020

16 July 2021

mechanism of action

1 reference

2 October 2019

computed tomography

1 reference

27 October 2020

1 reference

based on heuristic

inferred from title

bone density conservation agents

1 reference

16 July 2021

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Sten Nilsson

1

1 reference

language of work or name

1 reference

publication date

February 2016

1 reference

1 February 2016

8 references

13 March 2019

3 April 2019

19 June 2019

25 June 2019

2 October 2019

2 August 2020

27 October 2020

16 July 2021

Current Oncology Reports

7 references

19 June 2019

25 June 2019

2 October 2019

2 August 2020

27 October 2020

16 July 2021

18

1 reference

2

1 reference

14

1 reference

copyright license

Creative Commons Attribution 4.0 International

8 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

19 June 2019

Europe PubMed Central

25 June 2019

Europe PubMed Central

2 October 2019

Europe PubMed Central

2 August 2020

Europe PubMed Central

27 October 2020

Europe PubMed Central

16 July 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

20 March 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

7 April 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

7 April 2017

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

7 April 2017

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

7 April 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

7 April 2017

Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Enzalutamide in metastatic prostate cancer before chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Bone-targeting radiopharmaceuticals including radium-223.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

29 September 2017

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

2 June 2018

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715854

2 June 2018

Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS11912-015-0495-4

21 January 2018

Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11912-015-0495-4

21 January 2018

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

1 reference

https://api.crossref.org/works/10.1007%2FS11912-015-0495-4

21 January 2018

A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate canc

1 reference

https://api.crossref.org/works/10.1007%2FS11912-015-0495-4

21 January 2018

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective study of the time to clinical endpoints for advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Skeletal fractures negatively correlate with overall survival in men with prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abiraterone in metastatic prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11912-015-0495-4

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28079918&oldid=2177467774"